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Abstract
Introduction: Inflammation contributes to cardiovascular disease and is exacerbated with
increased adiposity, particularly omental adiposity; however, the role of epicardial fat is poorly
understood.
Methods: For these studies the expression of inflammatory markers was assessed in epicardial fat
biopsies from coronary artery bypass grafting (CABG) patients using quantitative RT-PCR. Further,
the effects of chronic medications, including statins, as well as peri-operative glucose, insulin and
potassium infusion, on gene expression were also assessed. Circulating resistin, CRP, adiponectin
and leptin levels were determined to assess inflammation.
Results: The expression of adiponectin, resistin and other adipocytokine mRNAs were
comparable to that in omental fat. Epicardial CD45 expression was significantly higher than control
depots (p < 0.01) indicating significant infiltration of macrophages. Statin treated patients showed
significantly lower epicardial expression of IL-6 mRNA, in comparison with the control abdominal
depots (p < 0.001). The serum profile of CABG patients showed significantly higher levels of both
CRP (control: 1.28 ± 1.57 µg/mL vs CABG: 9.11 ± 15.7 µg/mL; p < 0.001) and resistin (control:
10.53 ± 0.81 ng/mL vs CABG: 16.8 ± 1.69 ng/mL; p < 0.01) and significantly lower levels of
adiponectin (control: 29.1 ± 14.8 µg/mL vs CABG: 11.9 ± 6.0 µg/mL; p < 0.05) when compared to
BMI matched controls.
Conclusion: Epicardial and omental fat exhibit a broadly comparable pathogenic mRNA profile,
this may arise in part from macrophage infiltration into the epicardial fat. This study highlights that
chronic inflammation occurs locally as well as systemically potentially contributing further to the
pathogenesis of coronary artery disease.
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Cardiovascular disease (CVD) and its sequelae are the
leading cause of premature death, leading not only to sig-
nificantly increased mortality rates but also to high levels
of morbidity [1]. Whilst the causes of CVD are complex
there is increasing evidence suggesting an integral role for
inflammation in CVD pathogenesis, with recent research
examining therapeutics targeting this aspect of the disease
[2,3]. However, the cause of inflammation and its link
with CVD is still poorly understood, particularly in
humans, due to the difficulty in studying the relevant
human tissues.
Previous studies have highlighted the potential impor-
tance of adipose tissue in relation to inflammatory burden
in CVD, describing the expression and secretion of both
pro-inflammatory and protective factors, collectively
termed adipocytokines [4]. These factors include tumour
necrosis factor alpha (TNF-α), a pluripotent cytokine that
is a key mediator of the acute phase response that also
affects non-esterified fatty acid (NEFA) metabolism, as
well as myocardial contractility [5]. Resistin, a recently
identified adipocytokine, has been proposed as a poten-
tial link between obesity and inflammation and has been
linked to CVD risk [6,7]. Adiponectin exhibits both insu-
lin sensitising, anti-inflammatory and anti-atherogenic
properties with serum levels reduced in both type 2 diabe-
tes mellitus (T2DM) and coronary artery disease (CAD)
[8,9]. Kawanami et al have described directly reciprocal
effects of resistin and adiponectin with regard to inflam-
mation in vascular endothelial cells [10]. Adipose tissue
also produces further pathogenic adipocytokines includ-
ing plasminogen activator inhibitor-1 (PAI-1) and angi-
otensin II (ANG II), the active metabolite of
angiotensinogen (AGT), both important in the fibrino-
lytic and thrombotic pathways [11,12]. Adipose tissue
increases the production of these pathogenic adipocy-
tokines in obesity and it is hypothesised that macrophage
recruitment into adipose tissue may contribute to this
pathogenic response [13,14].
Studies have further established that adipose tissue distri-
bution has significant impact on disease risk with central
abdominal fat increasing both CVD and T2DM risk com-
pared with gluteo-femoral fat [15,16]. Such differences in
risk may be attributable to the depot specific differences in
the expression and secretion of adipocytokines [17,18].
However, whilst many investigations have elucidated the
relative pathogenic risk of abdominal and gluteo-femoral
adipose tissue, to date, few studies have investigated the
adipocytokine profile of epicardial adipose tissue. This
depot, situated predominantly on the right-ventricular
free wall and the left-ventricular apex [19], has been
shown to have a high capacity for non-esterified fatty acid
(NEFA) release and is proposed as a source of this pre-
ferred metabolite for the myocardium [20]. Whether adi-
pocytokines are also secreted directly into the cardiac
tissue is yet to be established and therefore the potential
paracrine effect of epicardial adipocytokines on myocar-
dial metabolism and their role in the pathogenesis of
CAD is as yet unknown. However, the lack of any fascia
between the adipocytes and the myocardial layer does
suggest that factors secreted by the adipocytes would read-
ily interact with the adjacent cardiomyocytes. Clinical
studies have noted a strong correlation between the fat
mass of epicardial adipose tissue, central abdominal fat
and the associated risk of T2DM and CVD [21]. Studies by
Mazurek and co-workers comparing expression of patho-
genic factors between epicardial and subcutaneous fat
from the leg in patients with CAD undergoing coronary
artery bypass grafting (CABG), also highlight the potential
importance of the inflammatory response of epicardial
tissue [22].
During the CABG operation, systemic metabolic substrate
infusions can be administered providing myocardial pro-
tection and promotion of post-operative myocardial func-
tion. This includes the glucose, insulin and potassium
(GIK) infusion. Both insulin and glucose can mediate
changes in adipocytokine expression; therefore, due to the
epicardial fat's proximity to the myocardium, there may
be significant paracrine action upon myocardial metabo-
lism through changes in adipocytokine secretion by this
depot. Consequently the aims of this present study were
to: 1) characterise the expression profile of adipocytokines
in epicardial fat from patients undergoing CABG com-
pared with adipose tissue from central and thigh fat from
those without CAD; 2) analyse serum levels of pro- and
anti-inflammatory cytokines in patients undergoing
CABG and case controls and finally; 3) assess the potential
effect of drug treatments and GIK infusion on epicardial
mRNA adipocytokine expression.
Materials and methods
Subjects
Tissue collection from CAD subjects
Human epicardial adipose tissue (n = 46) was collected
from CAD patients undergoing CABG (age: 53.8 ± 4.9 yr;
BMI: 27.5 ± 3.3 kg/m2), 10 of which were previously undi-
agnosed and untreated type 2 diabetics. Epicardial biop-
sies were taken approximately 1 hour post-anaesthetic,
with 24 randomised CAD patients receiving peri-opera-
tive infusions of GIK (500 mL 40% glucose, 40 mmol/L
KCl, 35 iu insulin (Actrapid, Eli Lilly, UK) at 0.75 mL/kg/
hr). All tissue was flash frozen immediately on removal,
prior to RNA extraction. During CABG sections of reversed
sapheno-femoral vein(s) are grafted into the aorto-coro-
nary position so bypassing significantly stenosed athero-
sclerotic segments of the epicardial coronary arteries. All
biopsies were collected in accordance with guidelines ofPage 2 of 7
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consent was obtained from all patients. Patients were on
a range of medications as outlined in Table 1.
Tissue collection from non-CAD subjects
Abdominal subcutaneous (n = 30), omental (n = 14) and
thigh (n = 13) adipose tissue was also collected from
patients without CAD or T2DM (age: 51.0 ± 7.5 yrs; BMI:
25.7 ± 4.7 kg/m2) undergoing elective surgery, in accord-
ance with guidelines of the South Birmingham ethics. All
tissue was flash frozen prior to RNA extraction.
Serum collection from CAD and non CAD subjects
Blood samples were taken prior to surgery and serum lev-
els of a panel of proteins (insulin, adiponectin, leptin,
CRP and resistin) were determined and compared to non-
diabetic control subjects with no known history of CAD
(n = 38, age: 38.0 ± 12.58 yrs; BMI 25.5 ± 2.34 kg/m2).
RNA extraction
RNA was extracted from samples using RNeasy Lipid Tis-
sue kit (Qiagen, UK) according to the manufacturer's
instructions. Extraction was followed by a DNase diges-
tion step to remove any contaminating genomic DNA.
RNA was quantitated using the Nanodrop ND-1000 Spec-
trophotometer (LabTech, UK) and 1 µg of RNA from each
sample was reverse transcribed using RevertAid™ H Minus
M-MuLV Reverse Transcriptase (Fermentas, UK) and ran-
dom hexamers, according to the manufacturer's instruc-
tions.
Real-time PCR
RT-PCR was performed in a reaction mix containing Taq-
Man Universal PCR Master Mix (AmpErase UNG), 100–
200 nmol TaqMan probe, 900 nmol primers and 25 ng
cDNA for all PCR reactions except resistin, where 115 ng
cDNA was utilised. All reactions were multiplexed with
the housekeeping gene 18S, provided as a pre-optimised
control probe (Applera, UK) enabling data to be expressed
as delta threshold cycle (∆Ct) values (where ∆Ct = Ct of
18s subtracted from Ct of gene of interest). Measurements
were carried out on at least three occasions for each sam-
ple. Reactions were as follows: 50°C for 2 minutes, 95°C
for 10 minutes; then 44 cycles of 95°C for 15 seconds and
60°C for 1 minute. Primer and probe sequences for resis-
tin, adiponectin, PAI-1, tissue plasminogen activator (t-
PA) and AGT were as previously described [17,18,23,24].
Leptin and CD45 primers were designed using Primer 3
[25] and their specificity determined using BLAST at
NCBI. Primers were designed to amplify across an exon/
exon boundary (leptin forward: ACC AAA ACC CTC ATC
AAG ACA ATT, leptin reverse: TCC AAA CCG GTG ACT
TTC TGT T, leptin probe: ATT TCA CAC ACG CAG TCA
GTC TCC TCC A, CD45 forward: CGT AAT GGA AGT GCT
GCA ATG T, CD45 reverse: CTG GGA GGC CTA CAC TTG
ACA, CD45 probe: ACA ACT AAA AGT GCT CCT CCA
AGC CAG GTC T). TNF-α and IL-6 expression were
assessed using a pre-designed gene expression assay-on-
demand kit (Applera, UK).
Data analysis
The expression of each gene was compared between
depots using the ∆∆Ct method [26]. All statistics were per-
formed at the ∆Ct stage in order to exclude potential bias
due to averaging of data transformed through the equa-
tion 2-∆∆Ct. Statistical analysis was undertaken using
ANOVA or two-tailed student t-test unless otherwise
stated (SPSS 12.0 for Windows, SPSS UK Ltd, UK).
Serum sample analysis
Resistin (R&D Systems, UK), CRP (Life Diagnostics Inc.,
USA), leptin, insulin and adiponectin (Biogenesis, UK)
and) were assessed by use of standard commercial ELISAs
all according to the manufacturers' recommended proto-
cols (Resistin intra-assay CV 4.7%, inter-assay CV 8.4%;
CRP intra-assay CV 4.4%, inter-assay CV 3.3%; Leptin
intra-assay CV 3.7%, inter-assay CV 4.0%; Insulin intra-
assay CV 5.96%, inter-assay CV 10.3%; Adiponectin intra-
assay CV 3.4%, inter-assay CV 5.7%;). Glucose concentra-
tion was determined using the YSI 2300 STAT PLUS
according to manufacturer's instructions.
Results
Gene expression in epicardial and abdominal depots
Epicardial adipose tissue was assessed for expression of
resistin, adiponectin, IL-6, CD45, AGT, TNF-α PAI -1, t-PA
and leptin by real time PCR. We determined that the
mRNA expression of resistin was 3 fold higher in epicar-
dial adipose tissue than in gluteal adipose tissue (P <
0.05), whilst epicardial resistin mRNA expression was
comparable with expression observed in the abdominal
fat depots (Figure 1). In contrast, adiponectin mRNA
expression was 5 fold higher in gluteal adipose tissue than
in epicardial adipose tissue (P < 0.01). Furthermore, the
level of adiponectin mRNA was also significantly lower in
the epicardial adipose tissue than in either of the abdom-
inal depots (P < 0.01) (Figure 1). IL-6 mRNA expression
Table 1: CAD Patient Medications
Medications % of total subjects (n = 46) 
receiving treatment
Statin 81
Aspirin 93
β-Blocker 75
ACEI 38
Ca2+ Channel Blockers 51
Nicorandil 34
Chronic treatments received by the CABG patient cohortPage 3 of 7
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with other abdominal depots (Table 2). CD45 was signif-
icantly increased in epicardial fat compared with abdom-
inal and thigh depots (thigh vs epicardial P < 0.01) (Table
2). The mRNA expression levels of AGT were also
increased in epicardial fat when compared with thigh fat
(P < 0.05), whereas the expression of PAI-1 was signifi-
cantly lower in the epicardial fat than either abdominal
subcutaneous or omental fat. Leptin mRNA expression
was significantly lower in both epicardial and omental
adipose tissue when compared with both abdominal sub-
cutaneous and gluteal adipose tissue, whilst TNF-α
showed no detectable difference across depots (Table 2).
In addition sub-group analysis of mRNA of all genes
between diabetic (n = 10) vs non-diabetic (n = 36) CABG
patients showed no significant differences.
The effect of drug treatment on epicardial gene expression
Treatment with β-Blockers, aspirin, ACE Inhibitors and
Ca2+ Channel Blockers did not affect the adipocytokine
gene expression in the epicardial adipose tissue (data not
shown). However whilst statins were also observed not to
affect the majority of adipocytokines the expression of IL-
6 was altered. The expression of IL-6 mRNA in those
CABG patients receiving statin treatment was reduced to
just 16% of the level expressed in those patients not
receiving statin treatment (Statin ∆Ct = 22.8 ± 0.48(mean
± SEM); Non-Statin ∆Ct = 20.1 ± 0.88, P = 0.028).
The effect of GIK infusion on epicardial gene expression
The comparison of gene expression between those CABG
patients receiving GIK infusion and those not receiving
GIK determined that there was no significant difference in
Expression of Resistin and Adiponectin mRNAFigure 1
Expression of Resistin and Adiponectin mRNA. mRNA levels of resistin and adiponectin mRNA expression are shown 
relative to epicardial fat (n = 46) which was arbitrarily assigned the value of 100% in abdominal subcutaneous fat (n = 30), 
omental fat (n = 14) and thigh fat (n = 13) (P-values: * P < 0.05, ** P < 0.01).Page 4 of 7
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not shown).
Serum sample analysis
The pro-inflammatory cytokine resistin was significantly
elevated in the serum of CABG patients when compared
to healthy, non-diabetic controls (P < 0.01) as were levels
of CRP (P < 0.001) (Table 3). In contrast, adiponectin was
significantly lower in CABG patients when compared to
controls (P < 0.05) (Table 3). No significant difference
was observed in serum leptin levels. Subgroup analysis of
diabetic versus non-diabetic CAD patients' serum, identi-
fied a significant difference in adiponectin levels (dia-
betic: 9.8 µg/mL ± 0.9 (mean ± SEM); non-diabetic: 12.7
µg/mL ± 1.0, P < 0.05).
Discussion
This study characterised the adipocytokine profile from a
unique human epicardial fat cohort comparing this with
other adipose tissue depots, evaluating the potential path-
ogenic paracrine role of epicardial fat on myocardial
metabolism. Our study established that metabolic risk
markers and pro-inflammatory agents, including resistin,
TNF-α and AGT were expressed at similar levels in epicar-
dial fat from CAD patients to those in omental abdominal
fat from non-CAD subjects. The impact of the excess
mRNA expression of these factors in epicardial fat may
represent an important and direct influence on myocar-
dial metabolism due to the intimate association of these
tissues. Unlike skeletal muscle there is no fascia separating
the myocardium from the adipose layer and both compo-
nents share the same coronary blood supply [19]. Previ-
ous studies have highlighted the paracrine role of ANG II
on cardiac function. Perfusion studies with rat hearts have
shown ANG II to reduce coronary flow and impair post-
ischaemic recovery [27]. As such, regional induction of
AGT/ANG II in human epicardial fat may further aggra-
vate myocardial dysfunction. Additionally, data suggest
that TNF-α, leptin and other adipocytokines may reduce
myocardial contractility implying another possible link
between epicardial adipocytokine secretion and cardiac
function [5,28,29]. We have also shown significantly
Table 2: Comparison of mRNA expression in Epicardial Fat from CAD patients with Fat Depots from non CAD Subjects
Human CAD 
Patients
Non-CAD Human Fat Depots
Epicardial n = 46 Abdominal SC n = 30 Omental n = 14 Thigh n = 13
∆Ct ± SEM ∆Ct ± SEM % Expression 
Relative to 
Epicardial
∆Ct ± SEM % Expression 
Relative to 
Epicardial
∆Ct ± SEM % Expression 
Relative to 
Epicardial
TNF-α 19.74 ± 0.36 19.19 ± 0.50 146 19.46 ± 0.20 121 19.86 ± 0.46 92
AGT 17.19 ± 0.31 18.08 ± 0.32 54 17.10 ± 0.62 106 18.16 ± 0.32 ↓51*
PAI-1 19.37 ± 0.41 18.01 ± 0.48 ↑257* 17.76 ± 0.54 ↑305* 19.76 ± 0.57 76
t-Pa 15.38 ± 0.24 16.38 ± 0.18 ↓50* 14.95 ± 0.32 135 16.73 ± 0.34 ↓39*
IL-6 23.08 ± 0.83 19.83 ± 0.99 ↑951* 18.19 ± 0.86 ↑2965** 21.52 ± 0.71 ↑295*
Leptin 15.31 ± 0.41 14.07 ± 0.23 ↑236* 16.50 ± 0.79 44 13.74 ± 0.21 ↑297**
CD 45 18.13 ± 0.46 21.46 ± 0.36 ↓10** 20.44 ± 0.27 ↓20** 19.79 ± 0.38 ↓32**
Expression of mRNA (∆Ct ± SEM) for each gene and depot was analysed. Expression in each depot was compared with that in epicardial adipose 
tissue from CAD patients which was arbitrarily assigned the value of 100%. Significant increases (↑) and decreases (↓) are highlighted (P-values: * P 
< 0.05, ** P < 0.01).
Table 3: Serum Biochemical Profile
Control Subjects CABG Patients Significance
BMI 25.5 ± 2.34 27.5 ± 3.3 N.S
Fasting Glucose (mmol/L) 5.5 ± 0.79 6.7 ± 0.2 P < 0.05
Fasting Insulin (IU/mL) 12.1 ± 0.9 12.1 ± 0.8 N.S
Resistin (ng/mL) 10.53 ± 0.81 16.50 ± 1.69 P < 0.01
CRP (µg/mL) 1.28 ± 1.57 9.11 ± 15.7 P < 0.001
Adiponectin (µg/mL) 29.1 ± 14.8 11.9 ± 6.0 P < 0.05
Leptin (ng/mL) 23.4 ± 4.2 18.5 ± 3.4 N.S
The clinical characteristics are noted between control non-CABG and CABG patient including adipocytokine serum profile, as well as fasting insulin 
and glucose levels. Values are means ± SEM except BMI (Mean ± SD), N.S represents non-significance.Page 5 of 7
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adipose tissue which supports the previous study showing
lower adiponectin protein content in the epicardium of
CABG patients when compared with non-CAD subjects
[30]. With both anti-inflammatory and anti-atherogenic
properties, local secretion of this adipocyte specific mole-
cule may well be important for healthy heart function and
as such a reduced level of expression by epicardial fat may
represent an important factor in the development of CAD.
We further addressed the potential contribution of macro-
phages towards the increased inflammatory gene expres-
sion profile in epicardial fat compared with other fat
depots. Utilising CD45 mRNA expression as a marker for
macrophages, we determined that epicardial adipose tis-
sue showed high levels of macrophage infiltration when
compared with fat depots from non-CABG subjects. Previ-
ous studies have similarly highlighted increased macro-
phage infiltration in epicardial fat [22]. The high level of
macrophage infiltration/activation in this depot indicates
that significant local inflammation is occurring. Macro-
phages are known to express high levels of many inflam-
matory adipocytokines including resistin [31] and may
well account for much of the inflammatory profile of gene
expression observed. In this context it is notable that epi-
cardial fat in this study showed low levels of expression of
IL-6 mRNA compared with other abdominal fat depots.
Whilst reports have implicated IL-6 as a pro-inflammatory
cytokine, recent studies have suggested anti-inflammatory
properties [32,33]. It is clear that IL-6 levels are raised in
the inflammatory state but whether this is as an integral
part of the response or in reaction to it remains equivocal.
Furthermore, serum levels of both IL-6 and TNF-α are
raised in the CAD patients [34] implying that the decrease
in IL-6 expression is localised to the epicardial tissue. If, as
suggested by Febbraio, Pedersen and others, IL-6 plays an
anti-inflammatory role and is beneficial to both glucose
uptake and lipid metabolism then the lower levels of
mRNA expression in the epicardial adipose tissue of
CABG patients may serve only to heighten dysfunction in
myocardial fuel metabolism [32,33]. The picture is further
complicated by our finding that IL-6 expression is dramat-
ically reduced in those subjects on statin treatment. Previ-
ous studies have shown that statin treatment can reduce
circulating levels of IL-6 [35], as well as its expression in
specific cell types including circulating monocytes [36].
Systemic serum analysis of patients undergoing CABG
determined raised resistin and CRP levels, whereas adi-
ponectin levels were decreased, this reduction being exac-
erbated in CAD patients with diabetes. The anticipated
reduction in adiponectin serum levels confirmed previous
reports [37], with a negative correlation between serum
CRP and adiponectin levels already identified [38]. How-
ever this study is the first to report higher serum resistin
levels in CVD patients.
In conclusion, this study casts light on the role of human
epicardial adipose tissue as a potential paracrine and/or
endocrine tissue, specifically within the context of cardio-
vascular risk. Epicardial adipose tissue shows a similar
pattern of expression for a number of key adipocytokines
to that of omental adipose tissue. We have also confirmed
a high level of macrophage infiltration in this depot which
may contribute to the pathogenic gene expression profile
in this tissue. Omental adiposity has been shown to be an
independent predictor of metabolic risk, with increased
resistin, AGT and PAI-1 mRNA expression representing
important mediators of inflammatory, fibrinolytic and
thrombotic risk [16]. The low levels of adiponectin, which
is increasingly becoming associated with the metabolic
syndrome and cardiovascular risk [39], strengthens the
argument that in CABG patients epicardial adipose tissue
represents a negative influence on both cardiovascular
outcome and myocardial function. Due to the CAD
patients' history the myocardium may have been directly
affected by ischemic insult, the gene expression profile
that we have described may therefore not be representa-
tive of normal epicardial adipose tissue. Further studies
are required in order to evaluate the direct effect of these
factors on cardiomyocytes and to establish the role of the
epicardial fat depot in non-CAD subjects.
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